CARVYKTI (CILTACABTAGENE AUTOLEUCEL) IN
CHINA — ACCESS AND PRICING

Carvykti is an autologous CAR-T cell therapy. The patient's own T cells are collected through leukapheresis, sent to the manufacturing facility, and engineered to express a chimeric antigen receptor that recognises BCMA on myeloma cells. After lymphodepleting chemotherapy, the engineered cells are returned to the patient by intravenous infusion. What distinguishes Carvykti from other BCMA CAR-T products is its binding design. Most CAR-T receptors use a single antigen-binding domain. Cilta-cel uses two BCMA-binding domains (a so-called bivalent or dual-epitope design), which allows it to bind BCMA more strongly and may contribute to the depth and durability of its responses. In published clinical trials, Carvykti has produced very high rates of stringent complete response, including in heavily pre-treated patients, with progression-free survival data that have been among the strongest reported for BCMA-directed therapies. The product was developed jointly by Legend Biotech, a Chinese biotechnology company that originally developed the underlying construct under the name LCAR-B38M, and Janssen (Johnson & Johnson), which led international clinical development and commercial registration. Carvykti's regulatory history is therefore unusually layered: it has Chinese scientific roots, but commercial approval and supply have been driven through the Janssen partnership in Western markets.

International patients searching for Carvykti in China usually arrive with one of three expectations. The page tries to address all three honestly. Expectation 1 — "Carvykti is just cheaper in China" This is the most common assumption and the one most often wrong. Carvykti as a commercial product, with the same labelling and supply chain as in the United States or Europe, is not the typical pathway for patients treated in mainland China as of the most recent available information. The Chinese cell therapy ecosystem is built around domestically developed and approved products, with originator Western CAR-T cell therapies playing a more limited role compared with originator small-molecule drugs and antibodies. The most current regulatory and product status for Carvykti in mainland China should be confirmed with the treating hospital before any travel decision is made. Expectation 2 — "There must be a Chinese equivalent" This expectation is much closer to reality. China has at least two domestically approved BCMA CAR-T products for relapsed and refractory multiple myeloma — equecabtagene autoleucel (CT053, brand name Carteyva), and zevorcabtagene autoleucel — plus an active portfolio of trial-stage BCMA, GPRC5D, dual-target, and allogeneic CAR-T platforms. These products are not identical to Carvykti, but they target the same antigen, treat the same disease, and operate in the same clinical setting. For many patients, the practical question is not how to obtain Carvykti specifically, but which Chinese option offers the best fit on clinical, regulatory, and cost grounds. Expectation 3 — "I want a clinical trial of Carvykti in China" Cilta-cel originated from a Chinese trial, and the Chinese clinical roots of the underlying construct mean that Chinese investigators have meaningful experience with this generation of bivalent BCMA CAR-T technology. Active and historical Chinese cell therapy trials sometimes use the early development name (LCAR-B38M) or related dual-epitope constructs. Patients interested in this lineage may be candidates for related Chinese trials rather than for Carvykti as a commercial product. CancerFax helps assess whether such a trial is open and clinically appropriate for the case.

Some patients specifically want Carvykti, often because their oncologist has recommended it or because they have read about its trial data. In that case, the pathway is generally to access it in a country where it is approved and supplied — most commonly the United States, parts of Europe, the United Kingdom, Japan, or Canada — at a designated treatment centre authorised by the manufacturer. Practical realities for international patients: CancerFax's primary corridor is China, and the page does not pretend to coordinate Carvykti directly in Western markets. What CancerFax can do is help patients understand whether the cost-and-access trade-off favours Carvykti at home or abroad, or whether a Chinese-approved BCMA CAR-T is a reasonable alternative.

• Total cost of Carvykti treatment in the United States and Eu

  Total cost of Carvykti treatment in the United States and Europe runs into hundreds of thousands of US dollars before considering hospital, monitoring, and supportive care, with insurance coverage varying by country and patient situation

• International patients without local insurance generally pay

  International patients without local insurance generally pay out of pocket and require advance financial commitment from authorised treatment centres

• Visa, travel, accommodation, and stay duration of at least e

  Visa, travel, accommodation, and stay duration of at least eight to twelve weeks are part of the planning

• Manufacturer authorisation and product allocation can affect

  Manufacturer authorisation and product allocation can affect timeline; not every authorised centre treats international patients on the same timelines as domestic patients

Equecabtagene Autoleucel (CT053, Carteyva) An NMPA-approved fully human BCMA CAR-T product for relapsed or refractory multiple myeloma after at least three prior lines of therapy. Available through commercial channels at qualified Chinese cancer centres, with a clearer regulatory and pricing framework than trial-stage products. CancerFax has a dedicated guide on this product. Zevorcabtagene Autoleucel A second domestically developed BCMA CAR-T product approved in China for relapsed or refractory multiple myeloma. Available through specific authorised centres. Comparative durability data are still maturing. Trial-Stage BCMA, GPRC5D, and Dual-Target CAR-T Several Chinese academic centres run active trials of BCMA-only, GPRC5D-only, and dual-target BCMA-GPRC5D CAR-T platforms, including for patients who have already failed BCMA-directed therapy. CancerFax has dedicated guides on GPRC5D CAR-T and dual-target therapy in this context. Allogeneic and Off-the-Shelf Platforms Trial-stage allogeneic BCMA CAR-T platforms are emerging in Chinese centres for patients whose own T cells are not suitable for autologous CAR-T, or where rapid access is needed. CancerFax has a dedicated guide on off-the-shelf cell therapy.

This comparison is general and should not be read as one product being clinically superior to the other. Both target BCMA on myeloma cells, both produce meaningful responses, and both are accessed through different regulatory pathways. The decision is usually about regulatory access, cost, country of treatment, and centre experience rather than head-to-head clinical superiority.

Carvykti in Approving Western Markets Carvykti is among the most expensive cancer therapies in the world. The drug list price in the United States and Europe runs into the high six figures in US dollars per patient, before considering hospital admission, lymphodepletion, intensive monitoring, supportive care, and any complications. With public health system or private insurance coverage, patient out-of-pocket can be far lower; without coverage, the total commitment is generally not realistic for most international patients without specific funding arrangements. Equecabtagene Autoleucel and Other Chinese BCMA CAR-T Chinese-approved BCMA CAR-T products are meaningfully less expensive than Carvykti or other originator products in Western markets. Total cost in China still runs into a major financial commitment when hospital admission, lymphodepletion, monitoring, and supportive care are included, but is typically a fraction of the equivalent Western pathway. Trial-based access to investigational products can lower the drug component further. What Patients Should Plan For Beyond the Drug Specific pricing in any currency changes over time and should always be confirmed with the treating hospital. CancerFax helps patients understand realistic ranges before travel and the total cost of treatment, not just the drug price.

• Hospital admission for screening, lymphodepletion, infusion,

  Hospital admission for screening, lymphodepletion, infusion, and CRS/ICANS monitoring

• Bridging therapy if disease is progressing during the manufa

  Bridging therapy if disease is progressing during the manufacturing window

• Visa, accommodation, local transport, and interpreter suppor

  Visa, accommodation, local transport, and interpreter support for the in-country stay

• Possible ICU-level care if CRS or other complications are se

  Possible ICU-level care if CRS or other complications are severe

• IVIG replacement and structured follow-up after discharge

  IVIG replacement and structured follow-up after discharge

• Continuity of follow-up at home, including imaging, lab work

  Continuity of follow-up at home, including imaging, lab work, and disease monitoring

Carvykti is approved and supplied through authorised treatment centres in the United States, European Union, Japan, the United Kingdom, Canada, and selected other markets. Hong Kong, Macau, and Taiwan have separate regulatory systems with their own approvals and access pathways, which differ from those in mainland China. The information in this guide is focused on mainland China access realities and how international patients can use the Chinese cell therapy ecosystem responsibly. Patients in markets where Carvykti is locally approved should generally explore the local pathway first with their oncologist, since insurance, supply chain, and follow-up are usually simpler at home than abroad. CancerFax becomes most useful when local access is unavailable, unaffordable, or operationally difficult.

Frequently Asked Questions

Answers to common questions from patients and families.

This guide is for patient education and care navigation support only. It is not an official communication of Janssen, Legend Biotech, or any other manufacturer. Approval status, indications, pricing, hospital authorisation, supply chain, and treatment availability can change. The most recent regulatory and product information from the manufacturer and the treating hospital remains the operational reference. CancerFax has no exclusive commercial relationship with the manufacturers of Carvykti or any Chinese-approved CAR-T product mentioned in this guide. CancerFax does not promise access to any specific commercial product. The role of CancerFax is to help patients evaluate options realistically and connect them with qualified treating hospitals where appropriate. This page does not replace medical advice from a qualified oncologist or haematologist. Eligibility, treatment choice, response, side effects, cost, and outcomes vary from patient to patient. CancerFax does not provide emergency medical care. Patients with breathing difficulty, severe bleeding, seizures, sudden weakness, uncontrolled pain, fever during treatment, or rapidly worsening symptoms should contact their treating hospital or emergency services immediately.

Structured reference data summarizing key information for this topic.

Structured reference data summarizing key information for this topic.